Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil.
BACKGROUND
Even established and effective antiarrhythmic drugs (AADs) in atrial fibrillation (AF) are limited by their pro-arrhythmic and non-target organ side effects. Therefore the search continues for safer and effective new AADs.


OBJECTIVE
This review will examine a novel AAD, tedisamil--a multichannel potassium channel blocker--and its antiarrhythmic properties, focusing on AF.


METHODS
Review of the literature and studies assessing the effect of tedisamil in humans and animal models with atrial arrhythmia(s).


CONCLUSIONS
Tedisamil appears to be effective for rhythm restoration in acute-onset AF patients. The proven anti-ischemic effect with tedisamil may be an added benefit. Further studies with tedisamil are needed to confirm its safety and long-term efficacy.
Krishnamoorthy
Suresh
S
University Department of Medicine, Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK.
Lip
Gregory Y H
GY
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003521:Cyclopropanes / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015394:Molecular Structure
D000889:Anti-Arrhythmia Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003521:Cyclopropanes; C059921:tedisamil